OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 7, pp. 255-263
Open Access | Times Cited: 423
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 7, pp. 255-263
Open Access | Times Cited: 423
Showing 1-25 of 423 citing articles:
SARS-CoV-2 variant biology: immune escape, transmission and fitness
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 937
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 937
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 14, pp. 1279-1291
Open Access | Times Cited: 571
Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 14, pp. 1279-1291
Open Access | Times Cited: 571
Covid-19 Vaccines — Immunity, Variants, Boosters
Dan H. Barouch
New England Journal of Medicine (2022) Vol. 387, Iss. 11, pp. 1011-1020
Open Access | Times Cited: 378
Dan H. Barouch
New England Journal of Medicine (2022) Vol. 387, Iss. 11, pp. 1011-1020
Open Access | Times Cited: 378
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Ori Magen, Jacob Waxman, Maya Makov-Assif, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 17, pp. 1603-1614
Open Access | Times Cited: 268
Ori Magen, Jacob Waxman, Maya Makov-Assif, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 17, pp. 1603-1614
Open Access | Times Cited: 268
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
Baoqi Zeng, Le Gao, Qingxin Zhou, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 234
Baoqi Zeng, Le Gao, Qingxin Zhou, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 234
The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good
Kevin Bardosh, Alexandre de Figueiredo, Rachel Gur‐Arie, et al.
BMJ Global Health (2022) Vol. 7, Iss. 5, pp. e008684-e008684
Open Access | Times Cited: 221
Kevin Bardosh, Alexandre de Figueiredo, Rachel Gur‐Arie, et al.
BMJ Global Health (2022) Vol. 7, Iss. 5, pp. e008684-e008684
Open Access | Times Cited: 221
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
Carolyn T. Bramante, Jared D. Huling, Christopher J. Tignanelli, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 7, pp. 599-610
Open Access | Times Cited: 203
Carolyn T. Bramante, Jared D. Huling, Christopher J. Tignanelli, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 7, pp. 599-610
Open Access | Times Cited: 203
T cell immunity to COVID-19 vaccines
E. John Wherry, Dan H. Barouch
Science (2022) Vol. 377, Iss. 6608, pp. 821-822
Open Access | Times Cited: 175
E. John Wherry, Dan H. Barouch
Science (2022) Vol. 377, Iss. 6608, pp. 821-822
Open Access | Times Cited: 175
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 166
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 166
Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
BMJ (2022), pp. e072141-e072141
Open Access | Times Cited: 162
Jill M. Ferdinands, Suchitra Rao, Brian E. Dixon, et al.
BMJ (2022), pp. e072141-e072141
Open Access | Times Cited: 162
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
Ashley Fowlkes, Sarang K. Yoon, Karen Lutrick, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 11, pp. 422-428
Open Access | Times Cited: 161
Ashley Fowlkes, Sarang K. Yoon, Karen Lutrick, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 11, pp. 422-428
Open Access | Times Cited: 161
Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022
Mark W. Tenforde, Wesley H. Self, Manjusha Gaglani, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 12, pp. 459-465
Open Access | Times Cited: 159
Mark W. Tenforde, Wesley H. Self, Manjusha Gaglani, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 12, pp. 459-465
Open Access | Times Cited: 159
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
Alexander Wilhelm, Marek Widera, Katharina Grikscheit, et al.
EBioMedicine (2022) Vol. 82, pp. 104158-104158
Open Access | Times Cited: 145
Alexander Wilhelm, Marek Widera, Katharina Grikscheit, et al.
EBioMedicine (2022) Vol. 82, pp. 104158-104158
Open Access | Times Cited: 145
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Kirsten E. Lyke, Robert L. Atmar, Clara Domínguez Islas, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 7, pp. 100679-100679
Open Access | Times Cited: 144
Kirsten E. Lyke, Robert L. Atmar, Clara Domínguez Islas, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 7, pp. 100679-100679
Open Access | Times Cited: 144
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
Katherine E. Fleming-Dutra, Amadea Britton, Nong Shang, et al.
JAMA (2022) Vol. 327, Iss. 22, pp. 2210-2210
Open Access | Times Cited: 139
Katherine E. Fleming-Dutra, Amadea Britton, Nong Shang, et al.
JAMA (2022) Vol. 327, Iss. 22, pp. 2210-2210
Open Access | Times Cited: 139
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 7, pp. 689-699
Open Access | Times Cited: 133
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 7, pp. 689-699
Open Access | Times Cited: 133
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years
Ronen Arbel, Ruslan Sergienko, Michael Friger, et al.
Nature Medicine (2022) Vol. 28, Iss. 7, pp. 1486-1490
Open Access | Times Cited: 131
Ronen Arbel, Ruslan Sergienko, Michael Friger, et al.
Nature Medicine (2022) Vol. 28, Iss. 7, pp. 1486-1490
Open Access | Times Cited: 131
Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis
Wing Ying Au, Peter Pak‐Hang Cheung
BMJ (2022), pp. e069989-e069989
Open Access | Times Cited: 126
Wing Ying Au, Peter Pak‐Hang Cheung
BMJ (2022), pp. e069989-e069989
Open Access | Times Cited: 126
Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom
Catherine Hyams, Robert Challen, Robin Marlow, et al.
The Lancet Regional Health - Europe (2022) Vol. 25, pp. 100556-100556
Open Access | Times Cited: 124
Catherine Hyams, Robert Challen, Robin Marlow, et al.
The Lancet Regional Health - Europe (2022) Vol. 25, pp. 100556-100556
Open Access | Times Cited: 124
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
Stephen J. Kent, David S. Khoury, Arnold Reynaldi, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 6, pp. 387-397
Open Access | Times Cited: 119
Stephen J. Kent, David S. Khoury, Arnold Reynaldi, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 6, pp. 387-397
Open Access | Times Cited: 119
COVID-19 2022 update: transition of the pandemic to the endemic phase
Michela Biancolella, Vito Luigi Colona, Ruty Mehrian‐Shai, et al.
Human Genomics (2022) Vol. 16, Iss. 1
Open Access | Times Cited: 118
Michela Biancolella, Vito Luigi Colona, Ruty Mehrian‐Shai, et al.
Human Genomics (2022) Vol. 16, Iss. 1
Open Access | Times Cited: 118
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
Sharon Hui Xuan Tan, Alex R. Cook, Derrick Heng, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 6, pp. 525-532
Open Access | Times Cited: 112
Sharon Hui Xuan Tan, Alex R. Cook, Derrick Heng, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 6, pp. 525-532
Open Access | Times Cited: 112
CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques
Jinyan Liu, Jingyou Yu, Katherine McMahan, et al.
Science Immunology (2022) Vol. 7, Iss. 77
Open Access | Times Cited: 112
Jinyan Liu, Jingyou Yu, Katherine McMahan, et al.
Science Immunology (2022) Vol. 7, Iss. 77
Open Access | Times Cited: 112
Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
Mayan Gilboa, Gili Regev‐Yochay, Michal Mandelboim, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2231778-e2231778
Open Access | Times Cited: 110
Mayan Gilboa, Gili Regev‐Yochay, Michal Mandelboim, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2231778-e2231778
Open Access | Times Cited: 110
Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study
Katherine Adams, Jillian P. Rhoads, Diya Surie, et al.
BMJ (2022), pp. e072065-e072065
Open Access | Times Cited: 92
Katherine Adams, Jillian P. Rhoads, Diya Surie, et al.
BMJ (2022), pp. e072065-e072065
Open Access | Times Cited: 92
